Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

Josh H. Heinzerling, MD
Published: Tuesday, Nov 21, 2017



Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.

According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.
 
SELECTED
LANGUAGE


Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.

According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x